Recent Updates
Recently added Catalysts

Single-dose rabbit Anti-thymocyte Globulin induction

Phase 2

End-Stage Renal Disease | Monoclonal antibody | Nephrology |Sanofi|Last Updated: Dec 7, 2015

Target and mechanism

ModalityMonoclonal antibody

Also known as rabbit anti-thymocyte globulin

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment99

FDA Designations

No designations recorded

Clinical trial landscape

Single-dose rabbit Anti-thymocyte Globulin induction · 1 trial · 2 indications

Phase 2 1
NCT00906204Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney TransplantationEnd-Stage Renal Disease
COMPLETED99 Analytics
PHASE2COMPLETED
Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation
End-Stage Renal DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

Composite Endpoint of 5 Components: Fever, Hypoxia, Hypotension, Cardiac Events, and Delayed Graft Function
During first 7 days after kidney transplantation

The composite endpoint components and definitions are: * Fever: Body temperature ≥ 38.5˚C. * Hypotension: After rATG initiation, systolic blood pressure ≤ 90 mmHg requiring de novo treatment with vasopressors. * Hypoxia: During transplantation surgery, increase in FiO2 to ≥ 60% following rATG initiation. Following transplantation, starting in recovery room, FiO2 ≥ 50% or nasal cannula delivering ≥ 3 liters, either singly or combined, for \> 12 hours out of a 24 hour period. * Cardiac events: Myocardial Infarction, clinically significant dysrhythmia (atrial fibrillation, atrial flutter, ventricular fibrillation and ventricular tachycardia) * Delayed graft function (DGF): Requirement for dialysis within 7 days of transplantation

Secondary Endpoints

Patient Survival
12 months post-transplantation
Graft Survival
12 months post-transplantation
Acute Kidney Rejection
12 months post-transplantation
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Single-dose ThymoglobulinEXPERIMENTALBiological/Vaccine Single-dose rabbit Anti-thymocyte Globulin induction, 6 mg/kg IV infusion
Divided-dose ThymoglobulinACTIVE_COMPARATORBiological/Vaccine Divided-dose rabbit Anti-thymocyte Globulin induction, 1.5 mg/kg IV infusion QD x 4

Interventions

NameTypeDescription
Single-dose rabbit Anti-thymocyte Globulin inductionBIOLOGICAL6 mg of rATG administered in a single dose on the day of kidney transplantation
Divided-dose rabbit Anti-thymocyte Globulin inductionBIOLOGICAL6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria: * Subject capable of giving written informed consent, with end-stage kidney disease, who is a suitable candidate for primary kidney transplantation * Male or female subject who has reached legal age in the state where they reside and is at least 18 years of age * Deceased or liv...

Countries:United States
Unlock Eligibility Criteria